Skip to main content
. 2023 Dec 1;115(2):635–647. doi: 10.1111/cas.16033

TABLE 2.

BRCA1/2 pathogenic variants in Japanese patients with solid tumors who underwent 324‐gene somatic genomic profiling test (FoundationOne CDx)

Total (n) Patients with BRCA1 pathogenic mutations (n) Patients with BRCA2 pathogenic mutations (n) Patients with BRCA1/BRCA2 pathogenic comutations (n) Patients with BRCA1/BRCA2 pathogenic mutations (n, %)
Patients, n 3094 55 97 4 156 (5.0)
Cancer type
BRCA‐associated cancer Breast 196 2 15 0 17 (8.7)
Ovary/fallopian tube/peritoneal 253 26 7 0 33 (13.0)
Pancreas 263 1 12 0 13 (4.9)
Prostate 254 3 30 0 33 (13.0)
Total 966 32 64 0 96 (9.9)
Non‐BRCA‐associated cancer Colorectal 539 4 6 1 11 (2.0)
Biliary 229 3 4 2 9 (3.9)
Central nervous system 152 1 4 0 5 (3.3)
Sarcoma 138 1 3 0 4 (2.9)
Uterus 115 3 2 1 6 (5.2)
Uterine cervix 114 1 2 0 3 (2.6)
NSCLC 105 0 3 0 3 (2.9)
Head and neck 99 0 1 0 1 (1.0)
Stomach 85 2 2 0 4 (4.7)
Thyroid 78 0 0 0 0.0
Skin 75 1 0 0 1 (1.3)
Unknown primary 66 5 2 0 7 (10.6)
Esophagus 63 0 3 0 3 (4.8)
Urinary 63 1 1 0 2 (3.2)
Kidney 23 0 0 0 0.0
Thymus 14 0 0 0 0.0
Adrenal gland 11 0 0 0 0.0
Duodenum 11 1 0 0 1 (9.1)
SCLC 11 0 0 0 0.0
Neuroendocrine carcinoma 9 0 0 0 0.0
GIST 8 0 0 0 0.0
Neuroendocrine tumor 8 0 0 0 0.0
Mesothelioma 7 0 0 0 0.0
Liver 6 0 0 0 0.0
Soft tissue 6 0 0 0 0.0
Vagina 4 0 0 0 0.0
Testis 2 0 0 0 0.0
Others 87 0 0 0 0.0
Total 2128 23 33 4 60 (2.8)

Abbreviations: GIST, gastrointestinal stromal tumor; NSCLC, non‐small‐cell lung cancer; SCLC, small‐cell lung cancer.